^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jingzhuda (entinostat)

    i
    Company:
    EOC Pharma, EddingPharm, Syndax Pharma
    Drug class:
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
    Related drugs:
    Apply
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/29/2014
    Primary completion :
    05/05/2020
    Completion :
    06/25/2025
    HER-2 • ER • PGR
    |
    exemestane • Jingzhuda (entinostat) • goserelin acetate
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (NCT01038778)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    10/29/2009
    Primary completion :
    05/22/2019
    Completion :
    07/30/2025
    mTOR
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas (NCT03179930)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    06/07/2017
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    CTLA4
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS) (NCT03280563)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    12/26/2017
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HER-2 • PD-L1
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)
    Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (CA209-117) (NCT01928576)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    05/03/2024
    Initiation :
    11/06/2013
    Primary completion :
    04/04/2023
    Completion :
    04/04/2023
    EGFR • KRAS • ALK
    |
    EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation
    |
    Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)
    Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (NCT01349959)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    04/21/2011
    Primary completion :
    03/27/2014
    Completion :
    03/07/2025
    HER-2 • ER • PGR
    |
    HR positive • PGR negative
    |
    azacitidine • Jingzhuda (entinostat)
    Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents (NCT02936752)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/25/2024
    Initiation :
    06/23/2017
    Primary completion :
    10/01/2022
    Completion :
    03/21/2025
    CD4
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (ETCTN-9844) (NCT02453620)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/20/2024
    Initiation :
    02/12/2016
    Primary completion :
    04/22/2021
    Completion :
    08/30/2024
    HER-2 • CD86
    |
    HR positive • HER-2 negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Jingzhuda (entinostat) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) (NCT03838042)
    Phase 1/2
    University Hospital Heidelberg
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    05/26/2020
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    PD-L1 • TMB • MYC
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Jingzhuda (entinostat)
    Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer (WOOPS) (NCT03978624)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/05/2024
    Initiation :
    09/23/2020
    Primary completion :
    01/31/2024
    Completion :
    11/22/2026
    CD8
    |
    Keytruda (pembrolizumab) • cisplatin • Jingzhuda (entinostat)
    Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02780804)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    01/06/2017
    Primary completion :
    06/30/2021
    Completion :
    09/30/2021
    AFP
    |
    Jingzhuda (entinostat)
    Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (ENCORE 601) (NCT02437136)
    Phase 1b/2
    Syndax Pharmaceuticals
    Completed
    Last update posted :
    09/21/2023
    Initiation :
    07/01/2015
    Primary completion :
    09/29/2022
    Completion :
    09/29/2022
    PD-L1 • BRAF • ALK • MSI
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (Breast 49) (NCT03473639)
    Phase 1
    University of Virginia
    Completed
    Last update posted :
    11/01/2022
    Initiation :
    01/29/2019
    Primary completion :
    09/02/2021
    Completion :
    11/01/2022
    HER-2 • PGR
    |
    HER-2 negative
    |
    capecitabine • Jingzhuda (entinostat)
    Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing (NCT00828854)
    Phase 2
    Syndax Pharmaceuticals
    Completed
    Last update posted :
    06/30/2022
    Initiation :
    10/01/2008
    Primary completion :
    11/24/2009
    Completion :
    11/24/2009
    ER
    |
    ER positive
    |
    Jingzhuda (entinostat)
    Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (NCT03291886)
    Phase 2
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    06/21/2022
    Initiation :
    09/22/2017
    Primary completion :
    04/04/2019
    Completion :
    03/26/2021
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    exemestane • Jingzhuda (entinostat)
    Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (NCT02623751)
    Phase 1
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    06/21/2022
    Initiation :
    11/01/2015
    Primary completion :
    10/01/2020
    Completion :
    10/01/2020
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • exemestane • Lazcluze (lazertinib) • Jingzhuda (entinostat)
    Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer (ENCORE301) (NCT00676663)
    Phase 2
    Syndax Pharmaceuticals
    Completed
    Last update posted :
    05/11/2022
    Initiation :
    06/13/2008
    Primary completion :
    01/29/2011
    Completion :
    11/26/2012
    ER
    |
    ER positive
    |
    exemestane • Jingzhuda (entinostat)
    Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer (NRG-GY011) (NCT03018249)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/16/2021
    Initiation :
    10/11/2017
    Primary completion :
    04/18/2018
    Completion :
    03/12/2021
    PGR
    |
    Jingzhuda (entinostat)
    Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer (EOC103A3101) (NCT03538171)
    Phase 3
    Taizhou EOC Pharma Co., Ltd.
    Active, not recruiting
    Last update posted :
    07/09/2021
    Initiation :
    05/15/2018
    Primary completion :
    07/01/2021
    Completion :
    03/01/2023
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    exemestane • Jingzhuda (entinostat)
    Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (NCT01434303)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    05/20/2019
    Initiation :
    01/10/2012
    Primary completion :
    02/16/2016
    Completion :
    02/16/2016
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • lapatinib • Jingzhuda (entinostat) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp)
    Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer (NCT02833155)
    Phase 1
    Taizhou EOC Pharma Co., Ltd.
    Completed
    Last update posted :
    05/07/2019
    Initiation :
    08/29/2016
    Primary completion :
    07/18/2018
    Completion :
    07/18/2018
    ER • PGR
    |
    exemestane • Jingzhuda (entinostat)
    Chemotherapy With or Without Epigenetic Priming in NSCLC Patients (NCT01846897)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center
    Recruiting
    Last update posted :
    06/14/2017
    Initiation :
    04/01/2013
    Primary completion :
    04/01/2015
    Completion :
    11/01/2015
    EGFR • ALK
    |
    EGFR mutation • ALK translocation
    |
    gemcitabine • docetaxel • pemetrexed • irinotecan • Jingzhuda (entinostat) • Onureg (azacitidine oral)